Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

NCT06683755 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Nivolumab
DRUG: Relatlimab
DRUG: Ipilimumab

Sponsor

M.D. Anderson Cancer Center